ReviewPediatric nephrology (Berlin, Germany)1994
Lupus nephritis in childhood and adolescence.
Review in Pediatric nephrology (Berlin, Germany), 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Cyclophosphamide therapy for lupus nephritis: poor renal survival in Arab children.Pediatric nephrology (Berlin, Germany) · 2003Trial
- Seizures as a marker of severe multi-organ involvement in neuropsychiatric systemic lupus erythematosus: a diagnostic risk stratification study.Clinical rheumatology · 2026Article
- Article
- Infantile Systemic Lupus Erythematosus Presenting as Membranous Lupus Nephritis.Indian journal of pediatrics · 2026Article
- Correlation Between Systemic Inflammation Response Index and Systemic Immune-Inflammation Index and Disease Activity of Lupus Nephritis in Children.Children (Basel, Switzerland) · 2026Article
- Interdisciplinary Clinical Practice Guidelines for patient-centred management of juvenile-onset systemic lupus erythematosus.EULAR rheumatology open · 2025Article
- Clinical characteristics, disease flares, infections and their impact on kidney outcomes in pediatric lupus nephritis: A cohort study.Pediatric nephrology (Berlin, Germany) · 2025Article
- Clinicopathological differences in the activation pattern of the complement system between pediatric and adult lupus nephritis: a single centered retrospective study in Korea.Childhood kidney diseases · 2025Article
- Early-onset lupus nephritis.Clinical kidney journal · 2024Review
- Article
- Clinicopathological, Immunological, and Laboratory Parameters of Childhood Lupus Nephritis: A Study from Northeast India.Journal of laboratory physicians · 2023Article
- Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study.Pediatric nephrology (Berlin, Germany) · 2020Article
- The human glomerular endothelial cells are potent pro-inflammatory contributors in an in vitro model of lupus nephritis.Scientific reports · 2019Article
- Clinicopathological findings and outcome of lupus nephritis in Tunisian children: a review of 43 patients.The Pan African medical journal · 2017Article
- Enteric-coated mycophenolate sodium in pediatric lupus nephritis: a retrospective cohort study.Clinical and experimental nephrology · 2016Article
- Lupus nephritis in Egyptian children: a 16-year experience.Journal of nephrology · 2015Article
- Clinical features and mortality in Chinese with lupus nephritis and neuropsychiatric lupus: A 124-patient study.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2014Article
- Inpatient health care utilization by children and adolescents with systemic lupus erythematosus and kidney involvement.Arthritis care & research · 2013Article
- Increased IgE serum levels are unrelated to allergic and parasitic diseases in patients with juvenile systemic lupus erythematosus.Clinics (Sao Paulo, Brazil) · 2012Article
- Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population.Arthritis and rheumatism · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus nephritis in childhood usually presents after the age of 10 years, and presentation under 5 years is very rare. More males (F:M ratio 4.5:1) are affected than in adult-onset cases, but the ratio is the same in prepubertal and pubertal children. The incidence of clinically evident renal disease is greater at onset than in adults (82%), the usual presentation being with proteinuria, 50% having a nephrotic syndrome. Half the children show World Health Organisation class IV nephritis in renal biopsies. Neuropsychiatric lupus is present at onset in 30%, may complicate 50% at some point and remains a major problem. Prognosis has improved greatly over the past 30 years, at least in part the result of immunosuppressive treatment. Treatment of the initial phase may be guided by the severity of the renal biopsy appearances, more aggressive treatment including cytotoxic agents, i.v. methylprednisolone and perhaps plasma exchange, although the value of exchange is not established. Controversy persists as to the most effective cytotoxic treatment in the acute phase, both oral and i.v. cyclophosphamide and azathioprine being used in different units. In the chronic maintenance phase it seems established both clinically and histologically that addition of a cytotoxic agent improves outcome, but again the drug and route of administration are contentious. Azathioprine has the advantage of being safe for pregnancy and not gonadotoxic, whilst i.v. cyclophosphamide has been demonstrated to improve results over prednisolone alone in controlled trials and has advantages in non-compliant patients. No trial comparing the two regimes has been carried out, and one is needed. Today children much less commonly go into renal failure, and the main causes of actual death (15% of patients over 10 years) are now infections and extra-renal manifestations of lupus, principally neurological. Morbidity of the disease and the treatment remain a major problem, especially when treatment exacerbates complications of the disease itself, such as infections, osteonecrosis, thrombosis, vascular disease and possibly neoplasia.
Indexed as
Identifiers
8018506What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.